Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm a large cap biotech analyst at JPMorgan. Delighted to be continuing the conference this morning with Alnylam, driven by a number of members of the company's management team up on stage. And just as a housekeeping note, we don't have to switch room for Q&A this year. We're going to stay in this room. There's going to be mic runners if you want to raise your hand and ask a question. If you don't want to do it the old fashion, then you can also enter a question electronically on the portal and I can read it off the iPad out here or you can listen to my question if you don't want to ask your own. But with that, I will pass it over to the company's CEO, Yvonne Greenstreet, for the presentation.
Thanks, Jessica. I have to say it's wonderful to be here in person to give us an opportunity to share an update on our progress at Alnylam. And I'm delighted to be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
